307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3...

by Ralf Gutzmer, Caroline Robert, Gabriella Liszkay, Grant McArthur, Jacek Mackiewicz, Rodrigo Munhoz, Paolo Ascierto, Judit Olah, Paola Queirolo, Luis De La Cruz Marino, Kalpit Shah, Harper Forbes, Christian Hertig, Yibing Yan
Published 2020-11-01